Aligos Therapeutics (ALGS) Live Share Price, Invest From India

Aligos Therapeutics Stock Performance

as on September 30, 2026 at 2:16 pm IST

Day's Low
Day's High
$5.40
Day's Price Range
$5.68
$5.62
3.91%
Downside
1.07%
Upside
52 Week's Low
52 Week's High
$3.98
52-Week Price Range
$13.69
$5.62
29.18%
Downside
143.58%
Upside

Aligos Therapeutics share price movements today

Previous Close: $5.54
Open: $5.53
Volume: 101.7K
Market Cap: $34.6M
Day's Low - High: $5.40 - $5.68
52 Week Low - High: $3.98 - $13.69

Aligos Therapeutics Historical Returns

1 Month Return: -18.67 %
3 Month Return: -2.6 %
1 Year Return: -42.65 %
3 Year Return: -69.91 %
5 Year Return: -98.55 %

Aligos Therapeutics Stock Fundamentals & Key Indicators

Check Aligos Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$34.6M

EPS (TTM)

-7.3

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.76

Industry PE ratio

-2.66

PEG Ratio

0.00

EBITDA

-71.2M

Revenue (TTM)

31.5M

Profit Margin

99.18%

Return On Equity TTM

-160.72%

Aligos Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aligos Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Aligos Therapeutics	StrongBuy	$34.6M	-98.55%	-0.76	99.18%	0.00%
Revolution Medicines	StrongBuy	$43.2B	643.29%	-22.77	0.00%	0.00%
Moderna	Neutral	$78.8B	-47.13%	-24.72	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$133.4B	189.75%	30.38	86.04%	0.00%
Regeneron	Buy	$81.1B	24.01%	17.96	84.86%	0.49%

Stock Returns calculator for Aligos Therapeutics Stock including INR - Dollar returns

The Aligos Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Aligos Therapeutics investment value today

Current value as on today

₹61,858

Returns

-₹38,142

(-38.14%)

Returns from Aligos Therapeutics Stock

-₹42,653 (-42.65%)

Dollar Impact

₹4,511 (+4.51%)

Analyst Recommendation on Aligos Therapeutics Stock

Based on 3 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 3 analysts, 100% of analysts recommend a 'BUY' rating for Aligos Therapeutics. Average target price of $52.38

Aligos Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Aligos Therapeutics.

What analysts predicted

89.27%UPSIDE

Target Price

$52.38

Current Price

$5.62

Analyzed by

3 Analysts

High

$175

Target

$52.38

Low

$20

Aligos Therapeutics target price $52.38, a slight upside of 89.27% compared to current price of $5.62. According to 3 analysts rating.

Indian Investors' Interest in Aligos Therapeutics Stock

Search interest for Aligos Therapeutics Stock has decreased by -82% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 31, 2026 to September 30, 2026

Change:-82% versus previous 30 day period

Aligos Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	0	1	1	0	0	0	0	0	2	27
Gross Profit	0	0	1	0	0	0	0	0	2	27
Operating Income	-22	-26	-20	-20	-19	-18	-28	-21	-26	-1
EBITDA	-34	5	-18	-81	43	-15	-30	-19	-22	1
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-34	5	-19	-82	43	-15	-31	-19	-22	1
Income Tax Expense	0	0	0	0	0	0	0	0	0	2
Net Income	-34	5	-19	-82	43	-15	-31	-19	-23	-1
Net Profit Margin	100.00%	42.51%	100.00%	100.00%	100.00%	73.16%	100.00%	-52.07%	100.00%	100.00%

Aligos Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	4	13	15	3	2
Gross Profit	-1	-2	-3	4	13	15	3	1
Operating Income	-13	-54	-97	-128	-97	-88	-89	-87
EBITDA	-12	-49	-105	-124	-92	-83	-128	-22
Interest Expense	-	-	10	-	-	-	-	-
Depreciation	1	2	3	3	3	3	2	0
Income Before Tax	-13	-52	-108	-128	-95	-86	-130	-23
Income Tax Expense	-	0	0	0	0	0	0	0
Net Income	-13	-52	-108	-128	-96	-87	-131	-24
Net Profit Margin	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	57.46%

Aligos Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-34	5	-19	-82	43	-15	-31	-19	-23	-1
Operating Cash Flow	-22	-19	-20	-18	-20	-15	-24	-21	-23	-24
Investing Cash Flow	-88	39	10	19	-44	-39	47	-2	34	24
Financing Cash Flow	0	0	0	0	101	0	0	0	0	0
Change in Cash	-111	20	-9	1	36	-55	23	-23	11	0

Aligos Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-13	-52	-108	-128	-96	-87	-131	-24
Operating Cash Flow	-6	-46	-74	-115	-79	-78	-80	-82
Investing Cash Flow	-69	6	32	3	-26	44	-18	-37
Financing Cash Flow	99	85	192	78	0	88	0	101
Change in Cash	24	45	150	-33	-105	54	-98	-18

Global Institutional Holdings in Aligos Therapeutics

Check out the Institutions with significant holdings in Aligos Therapeutics.

Funds	Holdings
Michael Rockefeller	3.26%
Vanguard	3.22%
VANGUARD INDEX FUNDS	3.19%
Felix Baker	1.53%
Fidelity Concord Street Trust	0.78%

See all

Insights on Aligos Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, ALGS stock has moved up by 1.1%
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 169.0K → 27.77M (in $), with an average increase of 91.9% per quarter
POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -23.04M → -1.50M (in $), with an average increase of 1431.9% per quarter
NO EFFECT
Against Peers
In the last 3 years, Revolution Medicines, Inc. Common Stock has given 97.0% return, outperforming this stock by 166.9%
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 687.7% return, outperforming this stock by 730.4%

About Aligos Therapeutics

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.

Organisation	Aligos Therapeutics
Headquarters	One Corporate Drive, South San Francisco, CA, 94080, US
Industry	Biotechnology
CEO	Lawrence Blatt

Key Management of Aligos Therapeutics

Name	Title
Ms. Kristina Engeseth M.B.A.	Senior VP and Head of People & Culture
Dr. David B. Smith Ph.D.	Executive VP & Head of Chemical Operations
Dr. Lawrence M. Blatt MBA, Ph.D.	CEO, President & Chairman of the Board
Ms. Laura Kavanaugh	VP & Head of Legal
Mr. Nikhil Aneja	Principal Accounting Officer
Dr. Sushmita M. Chanda DABT, Ph.D.	Executive Vice President & Chief Development Officer
Dr. Tse-I Lin Ph.D.	Senior VP of Early Compound Development & Belgian Site Head
Dr. Kieron Wesson Ph.D.	Vice President & Head of Chemistry Manufacturing Controls
Ms. Lesley Ann Calhoun CPA	Executive VP, CFO & COO
Dr. Julian A. Symons DPHIL	Executive VP & Chief Scientific Officer

FAQs

What is Aligos Therapeutics share price today?

Aligos Therapeutics share price today is $5.62 as on September 30, 2026 at 8:46 am IST at the close of the market. Aligos Therapeutics share today touched a day high of $5.68 and a low of $5.40.

What is the 52 week high and 52 week low for Aligos Therapeutics share?

Aligos Therapeutics share touched a 52 week high of $13.69 on December 15, 2025 and a 52 week low of $3.98 on July 28, 2026. Aligos Therapeutics stock price today i.e. September 30, 2026 at 8:46 am IST is closed at $5.62,which is 58.95% down from its 52 week high and 41.21% up from its 52 week low.

What is Aligos Therapeutics's market capitalisation today?

Aligos Therapeutics market capitalisation is $0.00T as on September 30, 2026 at 8:46 am IST.

How to invest in Aligos Therapeutics Stock (ALGS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Aligos Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Aligos Therapeutics Stock (ALGS) from India?

Indian investors can start investing in Aligos Therapeutics (ALGS) shares with as little as ₹95.83000183105469 or $1 (as of September 30, 2026 at 6:45 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹958.30 in Aligos Therapeutics stock (as per the Rupee-Dollar exchange rate as on September 30, 2026 at 6:45 pm IST). Based on Aligos Therapeutics share’s latest price of $5.62 as on September 30, 2026 at 8:46 am IST, you will get 1.7794 shares of Aligos Therapeutics. Learn more about fractional shares .

What are the returns that Aligos Therapeutics has given to Indian investors in the last 5 years?

Aligos Therapeutics stock has given -98.55% share price returns and 29.42% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?